What’s next for the DESTINY-Breast04 trial? An interview with Toshinari Yamashita

One of the most talked about studies from this year’s American Society of Clinical Oncology Annual Meeting (ASCO, 3–7 June 2022, IL, USA) was the DESTINY-Breast04 trial. When Shanu Modi of Memorial Sloane Kettering Cancer Center (NY, USA) presented the results she was met with a standing ovation. It was met with much excitement as it's the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer. In this interview, we speak with a principal investigator of the trial Toshinari Yamashita (Kanagawa Cancer Center, Japan) to explore the trial further...